Ascent Pediatrics acetaminophen controlled-release beads NDA expected by end of 1997.
This article was originally published in The Tan Sheet
Executive Summary
ASCENT PEDIATRICS ACETAMINOPHEN CONTROLLED-RELEASE BEADS NDA FILING expected by the end of 1997 pending analysis of Phase III trial results, the company states in an April 25 initial public offering prospectus. Under development as an OTC treatment for pain and fever in children, Pediatemp beads would compete against marketed pediatric medications in liquid or chewable tablet forms, the company reports. As designed, the controlled-release product would enable eight-hour dosing, "rather than the four hours required for currently available products," Ascent states.